Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barré and reactive arthritis patients.
Weeks or months following Campylobacter infection, a small proportion of infected individuals develop Guillain-Barré syndrome (GBS) or reactive arthritis (ReA). Stool culture for Campylobacter is often negative in these patients, and serology is therefore the method of choice for diagnosing a recent infection with Campylobacter. This study developed a capture ELISA system to detect anti-Campylobacter IgA and IgM antibodies indicative of a recent infection. The sensitivity of the assay was 82.0% in uncomplicated Campylobacter enteritis patients, 96.2% in GBS patients who were culture-positive for Campylobacter, and 93.1% in culture-positive ReA patients, with a specificity of 93.0%. The assay allows identification of Campylobacter infection in patients with post-infectious neurological and rheumatological complications.
Ang
C W
CW
Department of Medical Microbiology, Academic Medical Center, Amsterdam, Department of Medical Microbiology, Reinier de Graad Gasthuis, Delft, The Netherlands. w.ang@amc.uva.nl
Krogfelt
K
K
Herbrink
P
P
Keijser
J
J
van Pelt
W
W
Dalby
T
T
Kuijf
M
M
Jacobs
B C
BC
Bergman
M P
MP
Schiellerup
P
P
Visser
C E
CE
D016918:Arthritis, Reactive / Q000276:immunology*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D002167:Campylobacter / Q000276:immunology / Q000302:isolation & purification*; D002169:Campylobacter Infections / Q000175:diagnosis* / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D020275:Guillain-Barre Syndrome / Q000382:microbiology*; D006801:Humans; D000091402:Prohibitins; D012680:Sensitivity and Specificity
D015415:Biomarkers; C000717331:PHB2 protein, human; D000091402:Prohibitins